Even as China's economy rises, its stocks' returns are hobbled by fraud and dodgy accounting World stock markets sag ahead of potentially pivotal Federal Reserve meeting, Scotland vote Allergan agrees to move forward with special shareholders meeting in December Trump Plaza shuts down, becomes 4th Atlantic City casino to close this year US producer prices likely rose only slightly in August, latest sign of mild inflation Beijing says deep sea rig that sparked standoff with Vietnam later found gas closer to China Russia's ruble drops to all-time low amid fears over fallout from economic sanctions Alibaba increases IPO price range to between $66 and $68 per share from $60 to $66 per share. As Fed meets, speculation swirls over possible change in Fed language on timing of rate hike Insurer Humana's board authorizes $2 billion in share repurchases» Read More
Today's the day Eli Lilly was expected to get a Food and Drug Administration decision on the first-ever one-a-day impotence drug. Right now, the company sells Cialis for use as needed. But men could pop this one every day--like an aspirin or multi-vitamin--so the drug would always be "on boa
In a remarkably candid "Open Letter" on the homepage of its web site Genentech is taking a step back from implementing its new restrictive policy over the use of the cancer drug Avastin in lieu of Lucentis for age-related macular degeneration (AMD), the leading cause of adult blindness. I had recently blogged about the company's action and angry reader response to it.
CNBC's Becky Quick traveled exclusively with Warren Buffett on a whirlwind tour of China and South Korea. All this morning on Squawk Box, she is reporting in-depth on the trip and what it tells us about Buffett's investment philosophy. In this excerpt from an interview with Buffett while he and Becky were flying to China, he talks about the prospects for his investment in that country and why the Chinese people should be petitioning to get one particular Berkshire Hathaway product.
Humana posted a sharply higher quarterly profit on Monday, above Wall Street's target, on continued strength in its Medicare health plans for the elderly and its plans for employers.
British insurer Resolution said on Monday it was dropping its recommendation of a 4.9 billion pound ($10.1 billion) bid from Standard Life, but taking a neutral stance on a rival bid from Pearl.
British insurer Resolution recommended shareholders accept a $10 billion offer from rival Standard Life on Friday and backed away from its proposed takeover of Friends Provident.
Insured losses from California wildfires could exceed $1.6 billion if the fires continued tospread, a risk modeling firm said Thursday.
Rumors that American International Group will take a large writedown were disputed Thursday in a report from CNBC's David Faber.
Aetna on Thursday posted a better-than-expected third-quarter profit as membership increased, and the health insurer raised its full-year forecast.
British insurer Aviva said Thursday that sales rose 24 percent in the first nine months of the year as the company won new business and benefited from a U.S. acquisition.
Firefighters battling 15 fires across Southern California got a break from slowing winds Wednesday, but major blazes burned unchecked for a fourth day.
Health insurer WellPoint said on Wednesday that third-quarter profit rose 7 percent, helped by higher membership and improved control of operating costs.
Wildfires continued to burn out of control across Southern California for a third day on Tuesday as 500,000 people fled the San Diego area, and firefighters made a desperate stand to save a mountain town ringed by flames.
The corporate headquarters of Sony Electronics has been closed Tuesday for the second day due to the wildfires ravaging Southern California.
Britain's Prudential reported a 15 percent rise in nine-month insurance sales on Tuesday, at the high end of forecasts, as strong growth in Asia and the United States offset a shrinking business at home.
Shares in British insurer Resolution climbed more than 3 percent in early trade on Monday on hopes of a 5 billion pound ($10.2 billion) bid from rival Standard Life, backed by Swiss Re.
My recent posts on Genentech trying to crack down on doctors using its cheaper cancer drug Avastin instead of the more expensive Lucentis to treat patients with age-related macular degeneration--elicited a lot of emails from readers all over the world.
Just months after launching what was hailed as a revolutionary new product, Pfizer is taking it off the market. And it has nothing to do with safety. It has everything to do with sales--or the lack, thereof. The world's biggest drug company only recently started direct-to-consumer advertising for Exubera, but it apparently didn't work.
Insurer UnitedHealth Group posted a better-than-expected 15 percent rise in quarterly profit Thursday, helped by its Medicaid and seniors businesses.
Europe's major stock indexes closed higher Wednesday, following a mixed morning, as a strong set of earnings from the likes of Coca-Cola and JPMorgan boosted investor confidence.
Get the best of CNBC in your inbox